CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Progenics Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Progenics Pharmaceuticals, Inc.
1 World Trade Center
Floor 47
Phone: (646) 975-2500p:646 975-2500 New York, NY  10007-0089  United States Fax: (914) 789-2817f:914 789-2817
This company ceased filing statements with the SEC on 7/2/2020.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202012/31/2019YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Interim Chairman of the Board AnnMacDougall 11/15/2019 11/8/2019
Interim Chief Executive Officer, Interim Chief Financial Officer, Director David W.Mims 56 3/27/2020 11/8/2019
Chief Operating Officer BenedictOsorio 62 1/1/2019 7/1/2005
10 additional Officers and Directors records available in full report.

Business Names
Business Name
Excelsior Life Sciences Ireland Limited
EXINI Diagnostics AB
MNTX Royalties Sub LLC
7 additional Business Names available in full report.

General Information
Number of Employees: 105 (As of 12/31/2019)
Outstanding Shares: 86,596,633 (As of 5/4/2020)
Shareholders: 64
Stock Exchange: NASD
Federal Tax Id: 133379479
Fax Number: (914) 789-2817
Email Address: info@progenics.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, December 30, 2023